RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer
暂无分享,去创建一个
J. Park | H. Jeon | In‐San Kim | E. Lee | Shin‐Yup Lee | J. Choi | S. Cha | Y. T. Kim | Y. Choi | Myung‐Hoon Lee | S. Jheon | S. Yoo | Jaehee Lee | W. Lee | Hyo‐Gyoung Kang | Jae-Yong Park | C. Kim | Eun Young Bae | E. Lee | In-San Kim | Hyun Cheol Lee | Myung Hoon Lee | Young Tae Kim
[1] Lijing Yao,et al. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes , 2015, Genome Biology.
[2] J. Park,et al. A Functional Polymorphism in CSF1R Gene Is a Novel Susceptibility Marker for Lung Cancer among Never-Smoking Females , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Kristen Jepsen,et al. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.
[4] T. Haferlach,et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 , 2013, Annals of Hematology.
[5] P. Pineau,et al. Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma. , 2012, Cancer epidemiology.
[6] E. Androphy,et al. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3 , 2012, Cell cycle.
[7] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[8] R. Shoemaker,et al. Library-free Methylation Sequencing with Bisulfite Padlock Probes , 2012, Nature Methods.
[9] P. Kiely,et al. RACK1, A multifaceted scaffolding protein: Structure and function , 2011, Cell Communication and Signaling.
[10] M. Kolev,et al. Complement in Cancer and Cancer Immunotherapy , 2011, Archivum Immunologiae et Therapiae Experimentalis.
[11] Qing-quan Li,et al. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway , 2011, Breast Cancer Research and Treatment.
[12] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[13] M. Sughrue,et al. Cancer and the Complement Cascade , 2010, Molecular Cancer Research.
[14] Toshihide Matsumoto,et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. , 2010, Lung cancer.
[15] Ying Chen,et al. The p300/CBP - associated factor is frequently down-regulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome , 2010, Cancer biology & therapy.
[16] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[17] Wen-juan Wang,et al. RACK1: A superior independent predictor for poor clinical outcome in breast cancer , 2009, International journal of cancer.
[18] L. Tanoue,et al. The new lung cancer staging system. , 2009, Chest.
[19] G. Daley,et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming , 2009, Nature Biotechnology.
[20] Xiaodong Feng,et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. , 2009, European journal of cancer.
[21] Peter Bühlmann,et al. p-Values for High-Dimensional Regression , 2008, 0811.2177.
[22] John D. Lambris,et al. Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.
[23] Jay Shendure,et al. Multiplex amplification of large sets of human exons , 2007, Nature Methods.
[24] P. Donnelly,et al. Replicating genotype–phenotype associations , 2007, Nature.
[25] L. Miller,et al. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints , 2007, Oncogene.
[26] Peter Horak,et al. Five genes from chromosomal band 8p22 are significantly down‐regulated in ovarian carcinoma , 2005, Cancer.
[27] J. Weinstein,et al. Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.
[28] Piet Gros,et al. Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.
[29] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[30] Robert Livingston,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.
[31] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[32] John O'Quigley,et al. Explained randomness in proportional hazards models , 2005, Statistics in medicine.
[33] Douglas F. Easton,et al. Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.
[34] Timothy R. Rebbeck,et al. Assessing the function of genetic variants in candidate gene association studies , 2004, Nature Reviews Genetics.
[35] Hidde Ploegh,et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. , 2004, Molecular cell.
[36] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[37] Daiqing Liao,et al. PCAF is a coactivator for p73-mediated transactivation , 2003, Oncogene.
[38] J. Wall,et al. Haplotype blocks and linkage disequilibrium in the human genome , 2003, Nature Reviews Genetics.
[39] A. Huttenlocher,et al. RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. , 2003, Molecular biology of the cell.
[40] A. Merdes,et al. Assembly of centrosomal proteins and microtubule organization depends on PCM-1 , 2002, The Journal of cell biology.
[41] G. Schatten,et al. Arrest of cell cycle progression during first interphase in murine zygotes microinjected with anti-PCM-1 antibodies. , 2002, Cell motility and the cytoskeleton.
[42] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[43] G. Plopper,et al. The WD protein Rack1 mediates protein kinase C and integrin-dependent cell migration. , 2001, Journal of cell science.
[44] B. Hengerer,et al. RACK1 IS UP‐REGULATED IN ANGIOGENESIS AND HUMAN CARCINOMAS , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] U. Schindler,et al. A Gain-of-function Mutation in STAT6* , 2000, The Journal of Biological Chemistry.
[46] M. Houslay,et al. The RACK1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform* , 1999, The Journal of Biological Chemistry.
[47] S. Berger,et al. p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.
[48] S. Berger,et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.
[49] R. Evans,et al. Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.
[50] B. Howard,et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.
[51] W. Zimmer,et al. PCM-1, A 228-kD centrosome autoantigen with a distinct cell cycle distribution , 1994, The Journal of cell biology.
[52] J. Caldwell,et al. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] K. Nishioka,et al. THE COMPLEMENT SYSTEM IN TUMOR IMMUNITY: SIGNIFICANCE OF ELEVATED LEVELS OF COMPLEMENT IN TUMOR BEARING HOSTS * , 1976, Annals of the New York Academy of Sciences.
[54] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[55] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[56] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[57] J. Gmiński,et al. Immunoglobulins and complement components levels in patients with lung cancer. , 1992, Romanian journal of internal medicine = Revue roumaine de medecine interne.